Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
MGZ Medical Genetics Center | RCV002288387 | SCV002580680 | likely pathogenic | Familial adenomatous polyposis 4 | 2022-04-08 | criteria provided, single submitter | clinical testing | |
Myriad Genetics, |
RCV002288387 | SCV004189055 | pathogenic | Familial adenomatous polyposis 4 | 2023-08-29 | criteria provided, single submitter | clinical testing | This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. |
Labcorp Genetics |
RCV003546755 | SCV004268802 | pathogenic | not provided | 2024-03-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys255*) in the MSH3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH3 are known to be pathogenic (PMID: 27476653, 37402566). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1709103). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005032230 | SCV005673168 | likely pathogenic | Endometrial carcinoma; Familial adenomatous polyposis 4 | 2024-04-16 | criteria provided, single submitter | clinical testing |